Stocktoria
Mirum Pharmaceuticals, Inc. MIRM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-07-18
Mirum Pharmaceuticals, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% |
| Net margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% |
| FCF margin | 10.5% | 2.8% | -38.1% | -156.3% | -693.8% |
| Return on assets | -2.8% | -13.1% | -25.3% | -38.4% | -28.5% |
| Return on equity | -7.4% | -39.0% | -65.7% | -95.5% | -69.9% |
| Current ratio | 2.67 | 3.10 | 4.45 | 2.94 | 3.91 |
| Revenue growth | 54.7% | 80.8% | 141.8% | 302.7% | — |
Source: SEC EDGAR filings · CIK 0001759425 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.